Ten-year oral toxicity study with Norlestrin in rhesus monkeys.
The long term effects of the oral contraceptive, Norlestrin, were evaluated in sexually mature female rhesus (Macaca mulatta) monkeys over a 10 year period. Norlestrin, a combination of norethindrone acetate and ethinylestradiol (50:1) was given orally on a continuous cyclic regimen of 21 d of dosing followed by 7 d without treatment. Groups of 16 monkeys each received the drug at dose levels of 0.05, 0.51, and 2.55 mg/kg representing multiples of 1, 10, and 50 times the human dose, respectively. A comparable group of 16 animals remained untreated and served as controls. Selected clinical and laboratory parameters were monitored throughout the study and all animals were necropsied and evaluated for gross and histopathologic changes. All dose levels were well tolerated and survival was not affected. There were no consistent treatment-related alterations in coagulation or other clinical laboratory parameters. Ophthalmologically, macular pigmentary anomalies were observed in all groups. Treatment-associated pathologic findings, representing exaggerated pharmacological responses with superimposed senile changes, including ovarian and uterine atrophy and dilatation of acini and ducts in the mammary gland. Periodic vaginal cytologic examination and mammary gland palpation did not demonstrate drug related changes. A small number of neoplasms was seen in all groups and a granulosa cell carcinoma of the ovary occurred in a control animal. The benign tumors consisted of three cutaneous papillomas: one in a low dose and one in a high dose animal, a uterine leiomyoma in one high dose animal, and a pancreatic duct adenoma in one low dose animal. The results of this study indicate that Norlestrin had no significant toxic manifestations or tumorigenic potential when administered on a cyclic regimen to female rhesus monkeys at levels up to 50 times the human dose for ten yr.
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens; D003276:Contraceptives, Oral / Q000633:toxicity*; D003277:Contraceptives, Oral, Combined / Q000633:toxicity*; D004338:Drug Combinations / Q000633:toxicity; D004997:Ethinyl Estradiol / Q000633:toxicity*; D005170:Factor X / Q000378:metabolism*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D008253:Macaca mulatta; D009640:Norethindrone / Q000633:toxicity* / Q000031:analogs & derivatives; D010976:Platelet Count; D011517:Prothrombin Time; D013256:Steroids / Q000652:urine; D013997:Time Factors
D001786:Blood Glucose; D002273:Carcinogens; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D013256:Steroids; D004997:Ethinyl Estradiol; C036657:norlestrin; D005170:Factor X; D005340:Fibrinogen; D009640:Norethindrone